You may be a day or two early, or even a week or two, but the news we've been waiting for for over 4 years is finally upon us. Need I remind you, we are CRUSHING the competition and will continue to benefit from our status as first to market and most thoroughly tested. A "PROVEN" product with a proven advantage:
"....National managed healthcare company WellPoint has revised its medical policy regarding non-invasive fetal aneuploidy screening, suggesting that it will begin covering tests such as Sequenom's MaterniT21 Plus test. WellPoint said that several studies support the use of non-invasive fetal DNA-based aneuploidy tests and noted that various organizations, including ACOG, have "concluded that there is sufficient evidence to support the use [of such] tests in select individuals at high risk for fetal aneuploidy"
Take advantage of the "fiscal cliff" panic to line your account with new shares. We are going to 8.50 and soon.